Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation by Pastori, Daniele et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
Age-related increase of thromboxane B2 and risk of 
cardiovascular disease in atrial fibrillation
Pastori Daniele1,*, Pignatelli Pasquale1,*, Farcomeni Alessio2, Nocella Cristina1, 
Bartimoccia Simona1, Carnevale Roberto3 and Violi Francesco1
1 I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University 
of Rome, Rome, Italy
2 Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Rome, Italy
3 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
* These authors have contributed equally to this work
Correspondence to: Violi Francesco, email: francesco.violi@uniroma1.it
Keywords: atrial fibrillation, aging, thromboxane, cardiovascular disease, platelet, Gerotarget
Received: March 07, 2016 Accepted: May 12, 2016 Published: June 05, 2016
ABSTRACT
Aging is strictly associated with an increased incidence of cardiovascular events 
(CVEs) in the general population. Mechanisms underlying the risk of CVEs are still 
unclear. Platelet activation contributes to the onset of cardiovascular complications. 
The incidence of atrial fibrillation (AF) increases with age, and the natural history 
of AF is often complicated by CVEs. We prospectively investigated the relationship 
between age, urinary thromboxane (Tx) B2, which reflects platelet activation, and 
CVEs in 833 AF patients. Median TxB2 level was 120 [66-200] ng/mg of urinary 
creatinine. At multivariable linear regression analysis, age (B: 0.097, p=0.005) and 
previous MI/CHD (B: 0.069, p=0.047) were associated with log-TxB2 levels. When 
we divided our population into age classes (i.e. < 60, 60-69, 70-79, ≥ 80 years), 
we found a significant difference in TxB2 levels across classes (p=0.005), with a 
significant elevation at 74.6 years. During a mean follow-up of 40.9 months, 128 CVEs 
occurred; the rate of CVEs significantly increased with age classes (Log-rank test, p 
< 0.001). TxB2 levels were higher in patients with, compared to those without, CVEs 
in patients aged 70-79 (p < 0.001) and ≥ 80 (p = 0.020) years. In conclusion, TxB2 
levels enhance by increasing age, suggesting that platelet activation contributes to 
CVEs in elderly patients with AF. 
INTRODUCTION
Cardiovascular events (CVEs) represent the main 
cause of morbidity and mortality in the elderly population 
[1]. Several mechanisms have been proposed so far to 
explain the age-related incidence of CVEs. Thus, the 
prevalence of cardiovascular risk factors, such as smoking, 
hypertension and diabetes increases in elderly people. Of 
note is that despite increasingly effective cardiovascular 
preventive strategies, a portion of patients still experience 
cardiovascular complications. 
Platelets play a key role in the process of athero-
thrombosis as indicated by primary and secondary 
interventional trials with aspirin, which irreversibly 
acetylates COX1 so preventing platelet formation of the 
pro-aggregating eicosanoid Thromboxane (TxB) A2. These 
trials demonstrated, a significant reduction of CVEs in 
patients treated with aspirin [2, 3]. While experimental 
studies demonstrated a relationship between platelet 
activation and aging in animals [4], data in humans are 
inconclusive because of unreliable methods to assess 
platelet activation or small sample size [5-7]. 
Atrial fibrillation (AF) is an interesting model 
to explore this issue. Thus, the natural history of AF is 
paradigmatic of the relationship between age and CVEs, 
as aging is associated with enhanced AF prevalence [8] 
and an abrupt increase of CVEs complications CVEs [9, 
10]. We speculated that platelet activation may increase 
by aging and be correlated with CVEs in AF. To explore 
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this hypothesis we measured the urinary excretion of TxB2 
which is a reliable marker of in vivo platelet activation 
and is independently associated with CVEs in AF. Aim 
of the study was therefore to investigate if in AF patients 
a relationship between aging, urinary TxB2 excretion and 
CVEs does exist. 
RESULTS
Mean age of patients was 72.8±8.4 years, and 45.6% 
were women; 86.7% had hypertension, 19.2% diabetes, 
and 15.5% heart failure (HF). Moreover, 15.2% had a 
previous stroke/ transient ischemic attack (TIA), 19.3% 
a previous myocardial infarction (MI)/coronary heart 
disease (CHD), and 8.9% smoked. 
TxB2 levels and age
Median TxB2 level was 120 [66-200] ng/mg of 
urinary creatinine. At multivariable linear regression 
analysis, age (B: 0.097, p = 0.005) and previous MI/
CHD (B: 0.069, p = 0.047) were associated with log-TxB2 
levels, after adjustment for gender, hypertension, previous 
stroke/TIA, diabetes, HF, smoking and statin treatment.
Then, we divided our population into age classes 
(see Methods) and we found a significant difference in 
TxB2 levels across classes (Figure 1, p = 0.005), with a 
significant elevation at 74.6 years (as estimated using 
shape-restricted B-splines with a change-point). 
TxB2 levels, age, and cardiovascular events
Comparison of characteristics of AF patients with 
and without CVEs is reported in Table 1. During a mean 
follow-up of 40.9±28.8 months, 128 CVEs occurred: 21 
fatal/non-fatal ischemic stroke, 25 fatal/non-fatal MI, 19 
CHD, 59 vascular deaths, and 4 TIA. Of these, 0 were in 
class 1, 19 in class 2 (8%), 71 in class 3 (18%) and 38 in 
class 4 (24%) (Log-rank test, p < 0.001, Figure 2).
TxB2 levels were significantly higher in patients 
with CVEs compared to those without in classes 3 (180 
[90-315] vs. 100 [58-180], p < 0.001) and 4 (162 [120-
362] vs. 130 [80-200], p = 0.020), but not in class 2 (p = 
0.145).
DISCUSSION
In this study we analyzed the relationship between 
platelet activation and aging by classifying AF patients 
according to decades of age and analyzing the association 
between platelet activation and CVEs. The novel finding 
of the present study is that TxB2 biosynthesis is closely 
related with aging, with a progressive increase across 
the decades and a significant elevation at age > 74 years. 
Prospective analysis demonstrated that poor vascular 
outcomes were more frequently detected in AF patients 
Figure 1: Excretion of urinary 11-dehydro-TxB2 according to age classes.
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pertaining to classes 3 and 4 (age ≥ 70 years), who 
disclosed the highest TxB2 values. 
Previous studies investigated the interplay between 
platelet activation and aging using ex vivo methods to 
assess platelet function, such as beta-thromboglobulin 
and platelet factor 4 [5]. Despite a relationship between 
platelet activation and aging emerged from previous 
studies, small sample size, lack of follow-up and, overall 
unreliability, of ex vivo tests assessing platelet activation 
limits definite conclusion.
Differently from these methods, urinary excretion 
of 11-dehydro- TxB2 is a more reliable test to explore 
platelet activation in vivo [11]. However, there are only 
two studies, which explored the interplay between urinary 
excretion of 11-dehydro-TxB2 with equivocal findings. 
Thus, Alessandrini et al. [7] studied serum TxB2 formation 
in 177 subjects undergoing laboratory screening for the 
presence of atherosclerotic risk factors. The Authors found 
no correlation between TxA2 formation and age. However, 
the overall young age of the cohort (mean age 48 years), 
and the relative small number of elderly included in the 
study (only 26 patients aged > 60 years old) may be 
responsible for this different result. Conversely, Reilly 
and Fitzgerald [6], in a study involving twenty apparently 
healthy volunteers, found an increase in vivo formation 
of TxA2 in older ( > 65 years) than younger ( < 40 years) 
subjects. 
Compared to these two previous studies, we 
included a much larger cohort of patients at risk of 
cardiovascular disease, which allowed us to assess in vivo 
platelet activation across decades of age. Furthermore, we 
analyzed the impact of platelet activation in a long-term 
follow up, and its interplay with aging. Our study has 
two potentially relevant clinical messages; 1) the increase 
of platelet activation across decades of age, 2) the close 
relationship between platelet activation and aging in the 
occurrence of CVEs. Regarding the first point, we showed 
that urinary excretion of 11-dehydro-TxB2 increases by 
advancing age, peaking after 70 years. The second finding 
indicates a close association between aging, platelet 
activation and CVEs, suggesting that in vivo platelet 
activation may be a mechanism accounting for CVEs in 
elderly population.
The study has implications and limitations. The 
Figure 2: Kaplan-Meier survival curves according to age classes.
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present study did not explore the mechanisms linking aging 
with platelet activation. Experimental study demonstrated 
that aging is associated with platelet activation and that 
reactive oxidant species have a role. In particular, Dayal 
et al showed that platelet production of H2O2 increases by 
aging and is associated with platelet activation in mice [4]. 
The plausibility of this finding relies on the role of H2O2 
to enhance platelet activation via activation of COX1 and 
eventually TxA2 [12]. Thus, further study is necessary to 
investigate the interplay between platelet H2O2 and CVEs 
in elderly population.
The clinical implication of this finding is that much 
more attention should be paid to optimize antiplatelet 
treatment in the elderly population at risk of CVEs. This 
issue is even more relevant taking into account that 1) 
aging negatively influences the ability of low-dose aspirin 
to inhibit TxB2 biosynthesis [13]; 2) aspirin treatment, 
in addition to anticoagulant therapy, is associated with a 
significant higher rate of major bleeding in AF [14]. 
As these data stem from AF population, further 
study will assess the relationship between TxB2, aging 
and CVEs in other at risk populations. A randomized 
interventional trial with drugs inhibiting platelet function 
(i.e. TxB2 receptor antagonists) [15], is warranted to 
explore the potential benefits of modulating platelet 
function in elderly. 
In conclusion, these findings indicate that AF 
patients over 70 years have significant elevation of 
platelet activation, which may contribute to the age-related 
increased risk of CVEs. 
MATERIALS AND METHODS
Baseline urinary 11-dehydro-TxB2 (ng/mg of urinary 
creatinine) levels were measured in 833 non-valvular AF 
patients treated with vitamin k antagonists (INR range 2.0-
3.0). Exclusion criteria: antiplatelet treatment, prosthetic 
heart valves, cardiac revascularization in the previous 
year, chronic infections, autoimmune diseases and active 
cancer.
At baseline, anthropometric data, as well as 
informations regarding concomitant treatments and 
comorbidities, were registered. Each patient provided a 
written informed consent before participating in the study. 
A urine sample was collected for all patients at baseline 
(see below).
The occurrence of the first CVE during follow-
up was recorded and used for the survival analysis. The 
composite endpoint of CVEs included: fatal/non-fatal MI 
and stroke, CHD, TIA and vascular death. The definitions 
and adjudication of outcomes have been previously 
reported [16].
Laboratory analysis
After collection, urine samples were stored at -80°C 
until use. Urinary excretion of 11-dehydro-TxB2 was 
measured by an ELISA commercial kit (Cayman). Data 
are expressed as ng/mg creatinine. Intra- and inter-assay 
coefficients of variation were 4.0% and 3.6%, respectively. 
Laboratory staff performing TxB2 analysis was unaware of 
clinical characteristics of patients and CVEs.
Statistical analysis
Categorical variables were reported as counts/
percentage and continuous variables as mean (±standard 
deviation) or median (interquartile range). Student 
unpaired t test and Mann-Whitney U test were used to 
Table 1:Baseline characteristics of the study cohort according to the occurrence of cardiovascular events.
Variables
Cardiovascular events
p value
No (n = 705) Yes (n = 128)
Age (years) 72.1±8.5 77.0±6.6 <0.001
Women (%) 46.1 43.0 0.563
Smokers (%) 9.1 7.8 0.737
CHA2DS2-VASc score# 3.0 [2.0-4.0] 4.0 [3.0-6.0] <0.001
Arterial Hypertension (%) 85.7 92.2 0.048
Diabetes mellitus (%) 18.2 25.0 0.049
Heart failure (%) 13.2 28.1 <0.001
History of stroke/ transient ischemic attack (%) 12.9 28.1 <0.001
History of myocardial infarction / coronary heart 
disease(%) 16.0 37.5 <0.001
Statins (%) 37.4 36.7 0.980
Thromboxane B2 (ng/mg creatinine)# 110.0 [60.0-187.5] 162.5 [100.0-300.0] <0.001
#data expressed as median and interquartile range. 
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compare means and medians, and ANOVA or Kruskall-
Wallis test for groups comparison. Stepwise multivariable 
linear regression analysis was used to assess factors 
associated with log-TxB2 levels, including pre-specified 
variables. The cumulative incidence of CVEs according 
to age classes was estimated using Kaplan-Meier survival 
analysis. P values < 0.05 were considered as statistically 
significant. All tests were two-tailed and analyses were 
performed using SPSS-18.0, SPSS Inc. 
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